Scarica l'app Stockscreener
24.62
5.71%
-1.49
Precedente Chiudi:
$26.11
Aprire:
$26.11
Volume 24 ore:
51,792
Relative Volume:
1.88
Capitalizzazione di mercato:
$230.47M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-13.61%
1M Prestazione:
-7.23%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$24.62
$26.85
Intervallo di 1 settimana:
$24.62
$29.45
Portata 52W:
$15.80
$34.31
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Nome
Tvardi Therapeutics Inc
Settore
Industria
Telefono
(713) 489-8654
Indirizzo
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Confronta TVRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
24.62 | 230.47M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-12 | Iniziato | Piper Sandler | Overweight |
| 2025-05-21 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
Mostra tutto
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - marketscreener.com
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com India
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target - marketscreener.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - FinancialContent
BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target - marketscreener.com
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi: Q1 Earnings Snapshot - Huron Daily Tribune
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Tvardi Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com
Form 8-KCurrent report - ADVFN
TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia
Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq
TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz
Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com
Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com UK
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Conne - GuruFocus
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India
Cara Therapeutics approves merger and stock plans - Investing.com
Tvardi Therapeutics Inc Azioni (TVRD) Dati Finanziari
Non sono disponibili dati finanziari per Tvardi Therapeutics Inc (TVRD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Tvardi Therapeutics Inc Azioni (TVRD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
| Posner Christopher | PRESIDENT AND CEO |
Aug 01 '24 |
Sale |
0.35 |
4,149 |
1,452 |
172,436 |
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):